A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations

ABSTRACTIntroduction Vildagliptin, a dipeptidyl peptidase-4 inhibitor, is indicated to cure type 2 diabetes mellitus (T2DM). This systematic literature search aims to assess the current knowledge about the clinical pharmacokinetics (PK) of vildagliptin to provide recommendations for clinical use to prevent the harmful effects of this drug.Methods The PubMed, Science Direct, EBSCO, Cochrane Central Register of Controlled Trials, and Google Scholar databases were screened for articles related to the clinical PK of vildagliptin using systematic search strategies.Results The literature search identified 2118 records, among which 28 were subsumed in this systematic review that fulfilled the inclusion standards.Conclusions This systematic review can help dose optimization among critically ill patients (e.g. renal impairment) without exposing them to the drug’s toxic effects.KEYWORDS: Pharmacokineticspeak plasma concentrationrenal impairmentsystematic reviewvildagliptin Article highlights Vildagliptin is recommended for type 2 diabetes mellitus patients as an add-on to diet and exercise to improve glycemic control.The clinical PK of vildagliptin has been summarized for the first time in a systematic review.The PK of vildagliptin in both healthy and ill populations is gathered in this review. It provides information on how different formulations, dosing times, diet, age, gender, BMI, and concurrent medications affect the PK of vildagliptin.The researchers can build and assess the PK model of vildagliptin with the help of the summarized PK data.Declaration of interestsThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Authors’ contributionsAll authors have contributed substantially to the design, extraction, analysis, and interpretation of data and have actively participated in drafting and revising the article. All authors agreed to submit the final version to the journal and agreed to be accountable for all aspects of the work.Availability of data and materialsAll data generated or analyzed during this study are included in the article or its supplementary information file.Supplementary materialSupplemental data for this article can be accessed online at https://doi.org/10.1080/17425255.2023.2288252Additional informationFundingThis paper was not funded.